Akari Therapeutics
AKTX
8 hedge funds and large institutions have $488K invested in Akari Therapeutics in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
50% more capital invested
Capital invested by funds: $326K → $488K (+$162K)
33% more funds holding
Funds holding: 6 → 8 (+2)
0% less ownership
Funds ownership: 0% → 0% (-0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cresset Asset Management
Chicago,
Illinois
|
+$33.9K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$31.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$29.4K |
| 4 |
Renaissance Technologies
New York
|
+$4.28K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$221 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$90.4K |
| 2 |
TC
Truvestments Capital
Sarasota,
Florida
|
-$93 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OFW
1
Omnia Family Wealth
Aventura,
Florida
| $237K | – | – | – |
|
2
Cerity Partners
New York
| $63.8K | – | – | – |
|
|
CAM
3
Cresset Asset Management
Chicago,
Illinois
| $49.7K | +$33.9K | +460 | New |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $48.1K | +$31.8K | +431 | New |
|
|
5
Renaissance Technologies
New York
| $46.1K | +$4.28K | +58 | +16% |
|
|
6
UBS Group
Zurich,
Switzerland
| $43.1K | +$29.4K | +399 | New |
|
7
Bank of America
Charlotte,
North Carolina
| $405 | – | – | – |
|
|
8
Osaic Holdings
Scottsdale,
Arizona
| $270 | +$221 | +3 | New |
|
|
CPG
9
Cornerstone Planning Group
Fairfield,
New Jersey
| $18 | – | – | – |
|
10
Morgan Stanley
New York
| $16 | – | – | – |
|
|
SM
11
Sabby Management
Miami Beach,
Florida
| – | -$90.4K | -1,212 | Closed |
|
|
TC
12
Truvestments Capital
Sarasota,
Florida
| – | -$93 | -1 | Closed |
|
AKTX Hedge Fund Activity: Q2 2024 in Review
8 of the 6,927 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q2 2024, worth a combined $488K — up 50% from $326K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new AKTX positions and 2 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Cresset Asset Management, opening a new position worth an estimated $33.9K. The largest seller was Sabby Management, exiting entirely with an estimated $90.4K sold.
- 8 institutional investors held Akari Therapeutics (AKTX) as of Q2 2024, up from 6 in Q1 2024.
- Funds reported $488K of Akari Therapeutics stock for Q2 2024, up 50% quarter-over-quarter.
- 4 funds opened new Akari Therapeutics positions in Q2 2024 and 2 closed out, a net change of +2 holders.
- The largest Akari Therapeutics buyer in Q2 2024 was Cresset Asset Management, an estimated $33.9K added.
- The largest Akari Therapeutics seller in Q2 2024 was Sabby Management, an estimated $90.4K sold.
Based on aggregated 13F filings for Q2 2024.